Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Glycogen Synthase Kinase 3 as an Anticancer Drug Target: Novel Experimental Findings and Trends in the Design of Inhibitors

Author(s): Dmitry I. Osolodkin, Vladimir A. Palyulin, Nikolay S. Zefirov

Volume 19 , Issue 4 , 2013

Page: [665 - 679] Pages: 15

DOI: 10.2174/1381612811306040665

Price: $65

Abstract

Glycogen synthase kinase 3 (GSK-3) is a ubiquitous serine/threonine protein kinase participating in numerous pathways. Very important among them are cancer-related pathways, such as Wnt pathway and nuclear factor κB pathway. The recent findings concerning possible applicability of GSK-3 inhibitors as anticancer agents are summarized in this review, and controversies in the data are highlighted. The most actual concepts of GSK-3 inhibitor design are also thoroughly discussed.

Keywords: Glycogen synthase kinase 3, molecular design, cancer treatment, kinase inhibitors, Wnt pathway


Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy